share_log

Morgan Stanley Maintains Equal-Weight on Third Harmonic Bio, Raises Price Target to $7

Morgan Stanley Maintains Equal-Weight on Third Harmonic Bio, Raises Price Target to $7

摩根士丹利维持对Third Harmonic Bio的同等权重,将目标股价提高至7美元
Benzinga ·  2023/08/11 09:16

Morgan Stanley analyst Michael Ulz maintains Third Harmonic Bio (NASDAQ:THRD) with a Equal-Weight and raises the price target from $5 to $7.

摩根士丹利分析师迈克尔·乌尔茨维持第三和谐生物(纳斯达克:TRD)同等权重,并将目标价从5美元上调至7美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发